



HAL
open science

Germinal defects of SDHx genes in patients with isolated pituitary adenoma

Grégory Mougel, Arnaud Lagarde, Frédérique Albarel, Wassim Essamet, Perrine Luigi, Céline Mouly, Magaly Vialon, Thomas Cuny, Frederic Castinetti, Alexandru Saveanu, et al.

► **To cite this version:**

Grégory Mougel, Arnaud Lagarde, Frédérique Albarel, Wassim Essamet, Perrine Luigi, et al.. Germinal defects of SDHx genes in patients with isolated pituitary adenoma. *European Journal of Endocrinology*, 2020, 183 (4), pp.369-379. 10.1530/EJE-20-0054 . hal-03223143

HAL Id: hal-03223143

<https://amu.hal.science/hal-03223143v1>

Submitted on 11 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Germinal defects of pseudohypoxia pathway genes**
2 **in patients with isolated pituitary adenoma.**
3

4

5 **Authors**

6 Grégory Mougel¹, Arnaud Lagarde¹, Frédérique Albarel², Wassim Essamet³, Perrine Luigi⁴,
7 Céline Mouly⁵, Magaly Vialon⁵, Thomas Cuny⁶, Frédéric Castinetti⁶, Alexandru Saveanu¹,
8 Thierry Brue⁶, Anne Barlier¹, Pauline Romanet¹

9

10 **Affiliations**

11 ¹Aix Marseille Univ, INSERM, MMG, Laboratory of Molecular Biology Hospital La
12 Conception, Marseille, France

13 ²Department of Endocrinology, Hospital La Conception, APHM, Marseille, France

14 ³Department of Pathology, Hospital La Timone, APHM, Marseille, France

15 ⁴Department of Endocrinology, Hospital Lapeyronie, CHU Montpellier, France

16 ⁵Department of Endocrinology, Hospital Larrey, CHU Toulouse, France

17 ⁶Aix Marseille Univ, INSERM, MMG, Department of Endocrinology, Hospital La
18 Conception, Marseille, France

19

20 **Short title:** *SDHx/MAX* genes in isolated pituitary adenoma

21

22 **Key words:** pituitary adenoma, SDH, 3PAs, pheochromocytoma, genetic testing,
23 pseudohypoxia

24

25 **Corresponding author**

26 Pr Anne Barlier, MD, PhD

27 Aix Marseille University, INSERM, MMG, UMR 1251

28 Faculté de Médecine La TIMONE, 27, Boulevard Jean Moulin 13385 Marseille Cedex 5,
29 France

30 Tel.: +33 491 69 87 89

31 Fax: +33 491 69 89 20

32 Email: anne.barlier@univ-amu.fr

33 **Attention PA, Pas and 3PAs**

34

35 **Grants:** all phases of this study were supported by grants from the Institut National de lutte
36 contre le Cancer (INCa), the MarMaRa Institute, and the French Ministry of Health.

37

38 **Disclosure:** The authors declare that they have no think to disclose.

39

40 **Abstract (250)**

41 The “3PAs” syndrome, associating pituitary adenoma (PA) and
42 pheochromocytoma/paraganglioma (PPGL), is sometimes associated with mutations in
43 PPGL-predisposing genes such as *SDHx* or *MAX*. In “3PAs” syndrome, PAs can occur before
44 PPGL suggesting a new gateway into *SDHx/MAX*-related diseases.

45 **Objective:** determine the *SDHx/MAX* mutations prevalence in patients with isolated PA and
46 characterize the PA of *SDHx/MAX*-mutated patients.

47 **Design:** Genes involved in PAs (*AIP/MEN1/CDKN1B*) or PPGLs (*SDHx/MAX*) were
48 sequenced in patients with isolated PA. Next, we conducted a review of cases of PAs in the
49 setting of “3PAs” syndrome.

50 **Results:** 263 patients were recruited. Seven (likely) pathogenic variants were found in *AIP*, 2
51 in *MEN1*, 2 in *SDHA*, and 1 in *SDHC*. The prevalence of *SDHx* mutations reached 1.1%
52 (3/263). Among the 31 reported patients with PA harbouring *SDHx/MAX* mutations (28 from
53 literature and these 3 cases), 6/31 (19%) developed PA before PPGL, and 8/31 (26%) had
54 isolated PA. The age of onset is older than in *AIP/MEN1*-mutated patients. The PAs were
55 mainly macroprolactinomas and a feature of intracytoplasmic vacuoles can be observed by
56 histological study.

57 **Conclusions:** For the first time, we found *SDHx* mutations in patients bearing PA with no
58 family or personal history of PPGL. For the moment, data are missing to determine the
59 benefit of *SDHx/MAX* genetic screening in these patients. Meanwhile we recommend that
60 patients with isolated PA must be carefully examined on family history of PPGLs. A family
61 history of PPGL, as well as the presence of intracytoplasmic vacuoles in PA, requires
62 *SDHx/MAX* genetic testing of patients.

63

64

Clinical Study

65

66

67 **Word count: 3527**

68

INTRODUCTION

70

71

72

73

74

75

76

77

78

79

80

81

82

Although Pituitary adenomas (PAs) are benign tumors, they could be responsible for clinical features due to hormonal disturbances and compression symptoms that are secondary to local invasion and that can lead to hypopituitarism. The reported prevalence of symptomatic PAs is up to 1 in 1000 (1). PAs are most frequently sporadic diseases, but are inherited in approximately 5 cases in 100. In these cases, PAs can be isolated as in familial isolated pituitary adenomas (FIPAs) due to *AIP* mutation (AIP; OMIM 605555); or occur in syndromic association such as 1) multiple endocrine neoplasia 1 (MEN1; OMIM 131100), predisposing patients mainly to primary hyperparathyroidism, endocrine duodeno-pancreatic tumors, and PA; and more rarely 2) multiple endocrine neoplasia 4 (MEN4; OMIM 610755), which represents a MEN1-like syndrome; or 3) Carney complex (CNC; OMIM 160980) with cutaneous manifestations, acromegaly, Cushing syndrome, myxoma and schwannoma (2). In syndromic forms or familial cases, patients can benefit from genetic screening to propose specific monitoring and genetic counselling.

83

84

85

86

87

88

89

90

The association between PA and pheochromocytoma/paraganglioma (PPGL) was first described by Iversen in 1952 (3). This association can occur during *MEN1* or independently (4, 5, 6, 7, 8). This condition, called “3PAs” syndrome (for pituitary adenoma/pheochromocytoma/ paraganglioma association) by Xekouki can be described as the co-occurrence of PA and PPGL without other features of MEN1 syndrome (4, 5, 9). This association is rare, with less than 100 cases published in 2019. The “3PAs” syndrome can be associated with germline mutations in genes responsible for predisposition to PPGL as genes encoding for SDH subunits or *MAX* (5, 6, 7, 8).

91

92

93

94

95

96

97

98

The objective of this study is to assess the involvement of the main PPGL-predisposed genes in patients with isolated PA and to study the PA characteristics of patients with *SDHx/MAX* mutations. For this purpose, (1) we determined the prevalence of germline mutations in *MEN1*, *CDKN1B*, and *AIP*, and in *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SDHAF2* (herein called *SDHx* genes) and *MAX* genes in a large series of patients for which genetic testing was performed for sporadic or familial isolated PA. (2) We reviewed the literature for published cases of PA in the setting of “3PAs” syndrome to determine if patients with PA and genetic mutation in PPGL-predisposed genes have phenotypic singularities compared to

99 patients with *AIP*, *MEN1*, *PRKARIA*, or *CDKN1B* mutation and those with non-genetically
100 determined PA.

101

102 **PATIENTS AND METHODS**

103 **Subjects**

104 All patients who underwent genetic testing in the context of an isolated PA without other
105 endocrine lesions at the molecular laboratory of Marseille Conception Hospital between
106 November 2016 and December 2018 were included. Written informed consent of all patients
107 for genetics analysis was obtained during one-on-one genetic counselling. The ethics
108 committee of Aix-Marseille University approved this study (approval number: 2018-13-12-
109 004).

110

111 **Next-generation sequencing (NGS)**

112 Genomic DNA was extracted with a QiaSymphony DS DNA Midi Kit (Qiagen, Courtaboeuf,
113 France) from blood lymphocytes (standard EDTA samples). Exons and 20 bp flanking introns
114 of *AIP* (NM_003977.2), *MEN1* (NM_130799.2), *CDKN1B* (NM_004064), *SDHA*
115 (NM_004168.2), *SDHB* (NM_003000.2), *SDHC* (NM_003001.3), *SDHD* (NM_003002.2),
116 *SDHAF2* (NM-017841.1), and *MAX* (NM_002382.3) were sequenced by next-generation
117 sequencing (NGS) using the QiaSeq library (Qiagen, Courtaboeuf, France) according to the
118 manufacturer's instructions. Libraries were sequenced on MiSeqDX (Illumina). The
119 alignment and variant calling were performed using the Biomedical Genomics Workbench
120 5.0.1 (Qiagen). Annotation was done using VariantStudio v2.2 (Illumina), according to the
121 HGVS guidelines (10).

122 Each variant was classified according to the guidelines of the American College of Medical
123 Genetics and Genomics (ACMG) in one of the five following classes (11):

124 Class 1: benign variant (BV)

125 Class 2: likely benign variant (LBV)

126 Class 3: variant of uncertain significance (VUS)

127 Class 4: likely pathogenic variant (LPV)

128 Class 5: pathogenic variant (PV)

129 *In silico* predictions were performed using Alamut Visual software (Interactive Biosoftware,
130 Rouen, France), including the conservation level, SIFT, PolyPhen-2, and the study of the
131 splicing impact. The population data from population database (gnomAD database,
132 <https://gnomad.broadinstitute.org/> last visit november 2019) and from inherited disease

133 databases: ClinVar, LOVD, and HGMD were collected. The variants with a frequency above
134 5% in the population were not retained. All PVs and LPVs were confirmed by Sanger
135 sequencing (the primers and protocols are available upon request).

136

137 **Explorations of *SDHx* mutations in pituitary adenomas**

138 To specify the role of the *SDHx* germinal mutation in the PA, both a SDH
139 immunohistochemistry (IHC) and a research of Loss of heterozygosity (LOH) were done on
140 the formalin-fixed paraffin-embedded (FFPE) slide achieved throughout surgical removal of
141 the pituitary adenoma, if available.

142

143 SDH IHC analysis

144 The investigation of the loss of protein SDH expression in neoplastic cells was performed
145 using commercially available polyclonal antibody against SDHB (Sigma Aldrich, reference
146 HPA002868, dilution of 1 in 150). If any component of the SDH complex was damaged, then
147 the entire SDH complex became unstable, releasing the SDHB subunit into the cytoplasm
148 where it degraded rapidly (12). The staining protocol (XT UltraView DAB v3, Benchmark
149 IHC/ISH module) included pre-treatment with cell conditioner 1, incubation with antibody at
150 37 °C, and incubation with Prep Kit 517 solution for 32 minutes, followed by counterstaining
151 with haematoxylin for 8 minutes.

152

153 Sanger sequencing for research of LOH in tumors

154 DNA was extracted from samples using a QIAamp DNA FFPE tissue kit (Qiagen). Using the
155 AmpliTaq Gold 360 Master Mix (ThermoFisher Scientific, Waltham, MA, USA), DNA was
156 amplified by PCR targeting exon 5 of *SDHC* or exon 13 of *SDHA* (primers available upon
157 request). After purification the PCR products were sequenced using the Sanger method on a
158 AB3500XLDX (ThermoFisher Scientific).

159

160 **Comparison of patients with “3PAs” syndrome and “non-3PAs” syndrome based on the 161 literature data.**

162

163 The characteristics of patients presented with PA and *SDHx/MAX* (likely)pathogenic variant
164 were compared to patients with *AIP*, *MEN1*, *PRKARIA*, *CDKN1B*-related PA and to patients
165 with non-genetically determined PA. The patients with non-genetically determined PA came
166 from the cohort reported by Daly et al. from a Belgian population (1). The *AIP* cases

167 corresponded to 64 published cases with their phenotype (a list of references is available upon
168 request). The *MEN1* cases were extracted from the UMD-MEN1 Database (13), the Carney
169 complex cases were from a literature review published by Cuny et al. (14), and the MEN4
170 cases were from reviews conducted by Alrezk et al. and Fredericksen et al. (15, 16).

171

172 **Statistical analyses**

173 Statistical analyses were performed using Prism v6.0 (GraphPad Software, La Jolla, CA,
174 USA). The patients' characteristics were compared using the two-tailed Fisher's exact test for
175 the qualitative variables and the non-paired non-parametric Mann-Whitney test for the
176 quantitative values.

177

178 **RESULTS**

179 A total of 263 patients were included (Table 1 and Supplemental Table 1). The mean age at
180 PA diagnosis was 29.3 years (8-78), and the mean age at genetic screening was 36.1 years (8-
181 79). The occurrence of PA was sporadic in 227 patients (86.3%), while 36 patients presented
182 with a familial history of PA (13.7%). By NGS sequencing, we found 295 variants, among
183 which 7 variants were classified as pathogenic, 5 as likely pathogenic, and 7 as VUS (Table 1,
184 Figure 1, Supplemental Table2, and Supplemental Table 3). Five PV and LPV were found in
185 patients with a familial history of PA out of 36, and 7 in patients with sporadic PA out of 227.
186 The odds ratio of harbouring a (likely)pathogenic variant in cases of family history of PA
187 against no history is then 5.069 (95% CI: 1.69 to 15.79, p=0.014). Among the sporadic cases,
188 5 mutations occurred in patients younger than 30 years (5/133), and 2 occurred in patients
189 older than 30 years. Among the 12 PVs and LPVs, we found 7 variants in *AIP*, 2 in *MEN1*, 2
190 in *SDHA*, and 1 in *SDHC* (Figure 1, and Supplemental Table 2). The medical histories of the
191 3 *SDHx*-mutated patients are described as follows and in the Table 2.

192

193 **Case presentation**

194 Case 1: A previously healthy male patient aged 17 presented with a recent history of severe
195 right visual loss, clinically objectified on the Monoyer scale (right eye: 4/10, left eye: 10/10).
196 The MRI revealed a large (>10 mm) pituitary mass, and his prolactin level was measured at
197 91 µg/L (reference range: 4.1-15.34 µg/L). The patient underwent a transsphenoidal surgery
198 debulking. The post-operative examination was without complications and demonstrated a
199 marked improvement in vision. The post-operative prolactin secretion was measured at

200 104µg/L. Cabergoline was initiated at a dose of 0.5 mg weekly; allowing prolactin
201 normalisation (3µg/L at 3 months).

202 A *SDHC*: c.405+1G>T, p.(?) heterozygous pathogenic variant was demonstrated. This variant
203 was present in population database at a weak allele frequency (Minor Allele Frequency –
204 MAF <0.001%). It was reported as causing the deletion of exon 5 and a shift in the reading
205 frame (17). The SDH IHC analysis of PA was positive (Table 2). The search for LOH in the
206 tumor was negative. A whole body CT and investigation of serum and urinary catecholamine
207 did not show signs of PPGL. The *SDHC* variant was absent in his mother.

208

209 Case 2: A male patient aged 42, with no personal and family history of endocrine disease,
210 consulted for an 18-month history of erection disorder and decreased libido. The primary
211 hormonal assessment found a low testosterone rate (0.64 ng/mL) and a pituitary profile with
212 FSH at 1.3 IU/L, LH at 2.7 IU/L and prolactin at 84µg/L supporting a central origin. The
213 cranial MRI showed a pituitary macroadenoma with a moderate suprasellar extension but no
214 visual pathway compression. In this clinical context, cabergoline at a dose of 0.5 mg weekly
215 was initiated with a good medical and biological response. The analysis of *SDHA* revealed a
216 heterozygous frameshift variant on exon 6 of the gene (c.757_758del, p.(Val253Cys*67)),
217 resulting in a premature stop codon. This variant was absent from gnomAD. So it was
218 classified as likely pathogenic.

219

220 Case 3: This male was diagnosed with isolated microprolactinoma at 37-year-old with a
221 notable family history of PA with macroprolactinoma in his family but without any PPGL
222 history. His brother died during the surgery of a massive pituitary adenoma. Prolactin
223 secretion was well controlled under cabergoline (PRL <10 µg/L), but secondary to side
224 effects a change to bromocriptine was made. Subsequently, prolactin levels were poorly
225 controlled due to poor adherence to therapy (16.6 to 40 µg/L). A neurosurgical removal was
226 performed. The analysis of PPGL genes found a heterozygous missense variant in exon 13 of
227 *SDHA* (c.1753C>T, p.(Arg585Trp)). This variant is present in population database (gnomAD
228 MAF: 0.0025%), but the *in silico* analysis predicted a deleterious impact and studies reported
229 this variant as pathogenic (18). So, the variant was classified as likely pathogenic. The SDH
230 IHC analysis was positive (Table 1), and the search for LOH by Sanger sequencing was
231 negative. Family members were not available to conduct a genetic family survey.

232

233 Literature review and phenotypic features in “3PAs” syndrome

234 After reclassification of the variants using ACMG criteria (11) and excluding patients
235 with VUS or (likely)benign variants, we found 23 published cases of “3PAs” syndrome with
236 *SDHx* or *MAX* (likely)pathogenic variants (Table 3) (4, 5, 6, 7, 8, 19, 20, 21, 22, 23, 24, 25,
237 26, 27). Among the 23 cases, 19 patients had *SDHx* (likely) pathogenic variants: 2 in *SDHA*, 9
238 in *SDHB* (39%, 9/23), 2 in *SDHC*, and 6 in *SDHD* (26%, 6/23); 4 patients had *MAX*
239 pathogenic variants. PA occurred before PPGL in 6 cases (6/23, 26%). Moreover, we also
240 found 5 published cases with an isolated PA and a mutation in *SDHx* (1 in *SDHA* and 4 in
241 *SDHB*), all of them had a family history of PPGLs (Table 4) (5, 28, 29, 30).

242 Overall, the *SDHx/MAX* patients with PA included those harbouring PPGL (n=23, Table3),
243 those with a family history of PPGL (n=6, Table 4), those without PPGL context (n=3 from
244 this study). Among these 31 *SDHx/MAX* patients, 4 had a family history of PA (Table 3 and
245 our case 3), among them only one without PPGL history (our case 3). They included 16
246 females and 14 males (sex ratio: 1.1/1, the sex is not specified for one patient). The diagnosis
247 of PA was on average at 42.4 years old (range: 16-72). There were 23 macroPAs, representing
248 74% of cases, and 4 microPAs (13%). The 2 most frequent types were prolactinoma (19/31,
249 61%) and GH-secreting adenoma (5/31, 16%) (Table 5).

250 Then, we compared these *SDHx/MAX* patients with those from published cases of
251 genetically determined PAs (i.e. due to mutations in *AIP*, *MEN1*, *CDKN1B* or *PRKARIA*) and
252 non-genetically determined PAs. The age of occurrence of PAs in the *SDHx/MAX* patients
253 (mean 42.4 years, range: 16 to 72) was older than in the *AIP* patients (mean 25.9 years, range:
254 10-60, p<0.001), in the *MEN1* patients (mean 34.2 years, range: 7-82, p=0.024), and in the
255 *PRKARIA* patients (mean 31 years, range: 16-55, p=0.007) (Figure 2 and Table 5).

256 The proportion of prolactinomas was identical in the *SDHx/MAX* patients and in the
257 control population from the cohort published by Daly et al. (61% versus 66%) (Table 5) (1).
258 However, the PAs of the 31 *SDHx/MAX* patients were larger (23/31 macroadenomas versus
259 29/68 in control population p=0.002). In fact, macroprolactinoma was more frequent in
260 *SDHx/MAX* population (15/31 versus 11/68 p=0.0013). The *SDHx/MAX* patients also
261 presented a disposition to have older age at PA diagnosis than in the control population (42.4
262 years versus 34.5 years) but not statistically significant (p=0.08).

263

264 DISCUSSION

265 Even if mutations in *MEN1*, *AIP*, *CDKN1B*, and *PRKARIA* genes are identified as
266 causal factors in family PA, in most cases, no genetic cause was found. For example, *AIP*

267 mutations are found in only 20% of FIPA cases (31). In France, according to the TENGEN
268 guidelines (Oncogenetic Network in Neuroendocrine Tumors), mutations in *AIP*, *MEN1*, and
269 *CDKN1B* genes are investigated in patients with PA with (i) family presentation, (ii)
270 syndromic association, or (iii) isolated and sporadic pituitary macroadenoma occurred before
271 age 30. *PRKARIA* is investigated only in patients with typical syndromic association. Of note,
272 in our cohort, several patients aged of more than 30 years with sporadic and isolated PA had
273 genetic testing on express request of the endocrinologist for notably aggressive or drug-
274 resistant PAs, which are features of *MEN1*- and *AIP*-related PAs. In our cohort, the
275 prevalence of mutations in *AIP* and *MEN1* was consistent with prevalence reported in
276 literature in patients with PAs with similar inclusion criteria (32, 33, 34, 35, 36, 37).

277 Recently, a novel syndromic association called “3PAs”, and involving PAs and PPGLs
278 was described, sometimes associated with germline mutations in *SDHx/MAX* genes (4, 5, 6, 8,
279 20). A literature review about *SDHx/MAX*-mutated patients with “3PAs” syndrome found 6
280 patients in which the PAs were prevalent to the PPGLs, and 5 patients having an isolated PA
281 (Tables 3 and 4), suggesting a new gateway into *SDHx/MAX*-related diseases. These data
282 raise several issues regarding: (i) the incidence of *SDHx/MAX* mutations in patients with
283 isolated PAs, (ii) the characteristics of patients with isolated PA harbouring these mutations,
284 and consequently (iii) whether *SDHx/MAX* genes might be tested in patients with isolated PA.

285
286 Herein, we demonstrated for the first time the presence of *SDHx/MAX* germline
287 mutations in patients with isolated PA without PPGL history. In our study, among 263
288 patients with isolated PA, we found 3 (likely) pathogenic variants in *SDHx* genes: 2 in
289 sporadic cases of PA, one in a patient with a strong family history of PAs. The mutation
290 prevalence rate was 1.1%. In 2015, Xekouki et al. studied the prevalence of *SDHx* germline
291 mutations in a cohort of 168 patients with PA, including 143 patients with isolated and
292 sporadic PA, 3 patients with sporadic “3PAs” syndrome, and 22 patients with family “3PAs”
293 syndrome (4). Three *SDHx* mutations were identified in patients with family “3PAs”
294 syndrome. No mutation was found in the patients presenting with isolated PA, probably
295 because the cohort included a high proportion of patients with ACTH-secreting PAs (118/168,
296 70%).

297 It should be noted that the presence of *SDHx* (likely) pathogenic variants in patients
298 with PA might be due also to a fortuitous association. In a study of Hoekstra et al., nonsense
299 *SDHA* mutations have been found at a frequency of 0.5% in healthy population (38).
300 Moreover, potentially (likely) pathogenic variants in *SDHx/MAX* genes, as loss of function

301 variants, are registered in gnomAD. However, we did not identify any *SDHx/MAX*
302 (likely)pathogenic variants in a cohort of 239 patients presented with hyperparathyroidism
303 and without a personal or family history of PPGL and PA (personal data). This datum is in
304 favour of a non-random association between *SDHx/MAX* (likely) pathogenic variants and the
305 PAs.

306 It is also true that the involvement of *SDHx/MAX* genes in PA tumorigenesis remains
307 unclear. We have shown here that the age of onset of PA in the *SDHx/MAX*-mutated patients
308 is higher than that of other tumour suppressor genes and is equivalent to that of controls. The
309 loss of expression of SDH within tumor tissue is not established in all patients as in the case 1
310 and 3 of our study. In the literature, among the 24 patients with PA and germline mutations in
311 *SDHx*, SDH IHC and LOH testing in tumor samples was conducted for 10, but a loss of
312 staining/LOH was not found in 2, which doesn't support the hypothesis that Knudson's double
313 hit in these cases. Nevertheless, the *Sdhb* +/- murine model is consistent with the involvement
314 of *SDHx* mutation in pituitary tumorigenesis (4). At 12 months old, the *Sdhb* +/- mice
315 developed hyperplastic adenohypophysis, as classically found in *AIP* deficient mice (39) and
316 in human PA due to *AIP*, *PRKARIA* mutations or *Xq26* microduplication (40, 41, 42). The
317 adenohypophyseal cells of *Sdhb*+/- mice showed several intranuclear abnormalities and
318 strong HIF- α cytoplasmic and nuclear staining consistent with the activation of the
319 pseudohypoxia pathway of *SDHx*-mutated tumors (4, 8, 43, 44, 45). Nevertheless in humans,
320 data on the over-risk of PA in *SDHx/MAX*-mutated patients is required to conclude on the
321 need of pituitary gland monitoring in symptomatic and asymptomatic carriers of *SDHx/MAX*
322 mutations.

323

324 On the other hand, *SDHx/MAX* genetic testing for patients with PA should be decided
325 also in considering (i) the low penetrance of *SDHx*-related manifestations, (ii) the possible
326 anxiety generated by this information for the patient and his family (iii) the exposure to
327 ionizing radiation related to lifetime monitoring, and (iv) the cost of the clinical follow-up.

328

329 Among the 3 variants identified in patients with isolated PA, 2 occurred in *SDHA*, and
330 1 in *SDHC*. In PPGL population, *SDHx* germline mutations are accounted for approximately
331 15% of all cases and for the half of the family cases. *SDHB* and *SDHD* mutations are the most
332 common, *SDHA* and *SDHC* mutations are less frequent (46). On a large series of *SDHA*-
333 PPGL, the penetrance was calculated at 10% at 70 years (47), while Benn et al. and Maniam
334 et al., using a Bayesian statistical approach, indicated an overall penetrance of 1.7% (95% CI:

335 0.8% to 3.8%) and 0.1%-4.9%, respectively (48, 49). In the same study, Benn et al. calculated
336 the *SDHC* penetrance at 8.3% (95% CI: 3.5% to 18.5%) (48). Consequently, the absence of
337 PPGL in our patients with *SDHA* or *SDHC* mutations and their families is not unexpected
338 since the penetrance of *SDHA/SDHC*-related PPGL is low and the age of disease onset is late.

339

340 To the current state of our knowledge, it seems obvious that the presence of
341 *SDHx/MAX* (likely) pathogenic variants in patients with isolated PA justifies a screening for
342 PPGLs via careful clinical examination, full body imaging, and the measurement of urinary
343 catecholamine levels (38). However data are missing to determine if the over-risk of PPGL in
344 *SDHx*-mutated family without family history of PPGL is equal to that of family with history
345 of PPGL, and if these patients require the same level of monitoring, especially for *SDHA*
346 asymptomatic carrier. The monitoring data of patients with *SDHB*, *SDHC*, *SDHD*, and
347 *SDHAF2* mutations as secondary findings in clinical exome and genome sequencing from the
348 ACMG will certainly provide some answers (50). In any case, patients with PA must be
349 carefully examined not only for their family history of PA but also of PPGL, particularly for
350 patients bearing macroprolactinomas. Considering literature data, in case of family history of
351 PPGL, a genetic screening of *SDHx/MAX* is absolutely required for a family member bearing
352 an isolated PA. For patients with isolated PA and any family history of PPGL the benefits of
353 *SDHx/MAX* genetic testing remains to be assessed.

354

355 A rare condition requesting *SDHx/MAX* genetic testing in patients with PA seems to be
356 the presence of tumoral intracytoplasmic vacuoles, a particular histological phenotype
357 reported in *SDHx*-related PAs (7, table 3). These vacuoles seem not to be mitochondrial or
358 endoplasmic reticulum parts (5) and should represent autophagic bodies, due to the
359 pseudohypoxia (45, 51, 52). Like in renal carcinoma (46), vacuolisation of the cytoplasm
360 should lead to perform *SDHB* (+/-*SDHA*) IHC and *SDHx* genetic analysis.

361

362 In conclusion, we found for the first time *SDHx* mutations in patients bearing PA
363 without any family or personal history of PPGL. The prevalence rate of 1.1% is similar to
364 those of *MEN1* in this indication, leading the question whether *SDHx/MAX* systematic genetic
365 screening is required for such patients. Data are missing to determine the benefit of
366 *SDHx/MAX* genetic testing of patients with isolated PA and any family history of PPGL.
367 *Vice-versa*, data on the over-risk of PA is needed to conclude on the monitoring pituitary
368 gland in symptomatic and asymptomatic carriers of *SDHx/MAX* mutations. Meanwhile we

369 recommend a careful examination of patients with isolated PA not only on family history of
370 PAs but also of PPGLs. A family history of PPGL, as well as the presence of intracytoplasmic
371 vacuoles in PA, requires *SDHx/MAX* genetic testing for PA patients.

372

373 **Acknowledgments:** We thank all the patients and their medical doctors and professors: Dr
374 Amouroux, Pr Archambeaud, Dr Bahougne, Dr Barat, Dr Baudin, Dr Bennet, Dr Buffet, Pr
375 Caron, Pr Chabre, Dr Chabrier, Pr Chevalier, Dr Coblenca, Dr Coffin-Boutreux, Dr
376 Cordroc's, Dr Dalm-Thouvignon, Dr Decoudier, Dr Decoux-Poulot, Pr Delemer, Dr
377 Demarquet, Dr Dequidt, Pr Drutel, Dr Esvant, Dr Fedala-Haddam, Dr Ferrière, Dr Flaus
378 Furmaniuk, Dr Frête, Dr Gall, Dr Gilly, Pr Goichot, Dr Guedj, Dr Guenego, Dr Haissaguerre,
379 Dr Hawken, Dr Hieronimus, Dr Houcinat, Dr Houdon-N'Guyen, Pr Kerlan, Dr Kalfallah, Pr
380 Klein, Dr Le Marc Hadour, Dr Leheup, Dr Loddo, Dr Luca, Dr Luigi, Dr Ly, Dr Metz, Dr
381 Morcrette, Dr Moutton, Dr Nivot-Adamiak, Dr Nizon, Dr Nunes, Dr Olivier, Dr Pascal, Dr
382 Pienkowski, Dr Pihan Le Bars, Dr Plas, Dr Poirsier-Violle, Dr Porquet Bordes, Dr Raingeard
383 Dr Ramos Morange, Dr Raynaud-Ravni, Pr Reynaud, Dr Rochette, Dr Roudaut, Pr Sadoul, Dr
384 Salle, Dr Schneebeli, Pr Sonnet, Pr Tabarin, Pr Teissier, Dr Telo, Dr Vautier, Dr
385 Velayoudom-Cephise, Dr Verbeke, Dr Vermalle, Dr Vezzosi, Dr Vierge, Dr Vital, Dr
386 Wagner, Dr Zagdoun. We thank the Pr Dominique Figarella-Branger and the Pr Henry
387 Dufour.

388

389 **Ethics approval and consent to participate:** All patients or their parents provided signed
390 consent for genetic testing. The present study was approved by the ethics committee of the
391 Aix Marseille University (N° 2018-13-12-004).

392

393 **Funding sources:** all phases of this study were supported by grants from the Institut National
394 de lutte contre le Cancer (INCa), and the French Ministry of Health

395

396 **Competing interests:** The authors declare that they have no competing interests

397

398 **Disclosure statements:** The authors declare that they have no think to disclose.

399

400

401 **REFERENCES**

- 402 1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, & Beckers A. High
403 prevalence of pituitary adenomas: A cross-sectional study in the province of Liège, Belgium.
404 *Journal of Clinical Endocrinology and Metabolism* 2006 **91** 4769–4775. (doi:10.1210/jc.2006-
405 1668)
- 406 2. Correa R, Salpea P, & Stratakis CA. Carney complex: an update. *European journal of*
407 *endocrinology* 2015 **173** M85–M97. (doi:10.1530/EJE-15-0209)
- 408 3. IVERSEN K. Acromegaly associated with pheochromocytoma. *Acta medica Scandinavica*
409 1952 **142** 1–5.
- 410 4. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, Mastorakos P,
411 Wassif CA, Raygada M, Rentia N, Dye L, Cougnoux A, Koziol D, La Luz Sierra M De,
412 Lyssikatos C, Belyavskaya E, Malchoff C, Moline J, Eng C, Maher LJ, Pacak K, Lodish M, &
413 Stratakis CA. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate
414 dehydrogenase defects in humans and mice. *Journal of Clinical Endocrinology and*
415 *Metabolism* 2015 **100** E710–E719. (doi:10.1210/jc.2014-4297)
- 416 5. Dénes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, Xekouki P, Moran L,
417 Kumar A, Wassif C, Fersht N, Baldeweg SE, Morris D, Lightman S, Agha A, Rees A, Grieve
418 J, Powell M, Boguszewski CL, Dutta P, Thakker R V., Srirangalingam U, Thompson CJ,
419 Druce M, Higham C, Davis J, Eeles R, Stevenson M, O’Sullivan B, ... Korbonits M.
420 Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma
421 and pituitary adenoma: Results from a large patient cohort. *Journal of Clinical Endocrinology*
422 *and Metabolism* 2015 **100** E531–E541. (doi:10.1210/jc.2014-3399)
- 423 6. Denes J, Swords F, Xekouki P, Kumar A V, Maher ER, Wassif CA, Fersht N, Grieve J,
424 Baldeweg SE, Stratakis CA, & Korbonits M. Familial pituitary adenoma and paraganglioma
425 syndrome-a novel type of multiple endocrine neoplasia. *Endocrine Reviews* 2012 **33** OR41–
426 OR42.
- 427 7. Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I, Neggers SJM, M,
428 Sacre N, Lely AJ van der, Bours V, Herder WW d., & Beckers A. Pheochromocytomas and
429 pituitary adenomas in three patients with MAX exon deletions. *Endocrine-Related*
430 *Cancer* 2018. pp L37–L42. . (doi:10.1530/ERC-18-0065)
- 431 8. Xekouki P, Pacak K, Almeida M, Wassif CA, Rustin P, Nesterova M, La Luz Sierra M De,
432 Matro J, Ball E, Azevedo M, Horvath A, Lyssikatos C, Quezado M, Patronas N, Ferrando B,
433 Pasini B, Lytras A, Tolis G, & Stratakis CA. Succinate dehydrogenase (SDH) D subunit
434 (SDHD) inactivation in a growth-hormone-producing pituitary tumor: A new association for
435 SDH? *Journal of Clinical Endocrinology and Metabolism* 2012 **97** 357–366.
436 (doi:10.1210/jc.2011-1179)

- 437 9. O'Toole SM, Dénes J, Robledo M, Stratakis CA, & Korbonits M. The association of pituitary
438 adenomas and pheochromocytomas or paragangliomas. *Endocrine-Related Cancer* 2015 **22**
439 T105–T122. (doi:10.1530/ERC-15-0241)
- 440 10. Dunnen JT den, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, Roux
441 AF, Smith T, Antonarakis SE, & Taschner PEM. HGVS Recommendations for the Description
442 of Sequence Variants: 2016 Update. *Human Mutation* 2016 **37** 564–569.
443 (doi:10.1002/humu.22981)
- 444 11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E,
445 Spector E, Voelkerding K, Rehm HL, Laboratories KD, Genetics M, Health O, Road P,
446 Molecular C, Children N, State O, Berindan-neagoe I, Monroig P, Pasculli B, George A,
447 Medicine T, Hatieganu PI, Juan S, Rico P, Sciences P, Richards S, ... Rehm HL. Standards and
448 Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of
449 the American College of Medical Genetics and Genomics and the Association for Molecular
450 Pathology Sue. *Genetics in Medicine* 2015 **17** 405–424. (doi:10.1038/gim.2015.30.Standards)
- 451 12. Ugalde C, Janssen RJRJ, Heuvel LP van den, Smeitink JAM, & Nijtmans LGJ. Differences in
452 assembly or stability of complex I and other mitochondrial OXPHOS complexes in inherited
453 complex I deficiency. *Human Molecular Genetics* 2004 **13** 659–667.
454 (doi:10.1093/hmg/ddh071)
- 455 13. Romanet P, Mohamed A, Giraud S, Odou MF, North MO, Pertuit M, Pasmant E, Coppin L,
456 Guien C, Calender A, Borson-Chazot F, Béroud C, Goudet P, & Barlier A. UMD-MEN1
457 Database: An Overview of the 370 MEN1 Variants Present in 1676 Patients from the French
458 Population. *Journal of Clinical Endocrinology and Metabolism* 2018 **104** 753–764.
459 (doi:10.1210/jc.2018-01170)
- 460 14. Cuny T, Mac TT, Romanet P, Dufour H, Morange I, Albarel F, Lagarde A, Castinetti F,
461 Graillon T, North MO, Barlier A, & Brue T. Acromegaly in Carney complex. *Pituitary* 2019 .
462 (doi:10.1007/s11102-019-00974-8)
- 463 15. Alrezk R, Hannah-Shmouni F, & Stratakis CA. MEN4 and CDKN1B mutations: the latest of
464 the MEN syndromes. *Endocrine-Related Cancer* 2017 **24** T195–T208. (doi:10.1530/ERC-17-
465 0243)
- 466 16. Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker R V, & Frost M. Clinical Features
467 of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published
468 Cases. *The Journal of Clinical Endocrinology & Metabolism* 2019 **104** 3637–3646.
469 (doi:10.1210/jc.2019-00082)
- 470 17. Niemann S, Müller U, Engelhardt D, & Lohse P. Autosomal dominant malignant and
471 catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC.
472 *Human genetics* 2003 **113** 92–94. (doi:10.1007/s00439-003-0938-0)
- 473 18. Casey RT, Ascher DB, Rattenberry E, Izatt L, Andrews KA, Simpson HL, Challis B, Park S

- 474 mi, Bulusu VR, Lalloo F, Pires DE V, West H, Clark GR, Smith PS, Whitworth J, Papathomas
475 TG, Taniere P, Savisaar R, & Hurst LD. SDHA related tumorigenesis : a new case series and
476 literature review for variant interpretation and pathogenicity. 2017 237–250.
477 (doi:10.1002/mgg3.279)
- 478 19. Roszko KL, Blouch E, Blake M, Powers JF, Tischler AS, Hodin R, Sadow P, & Lawson EA.
479 Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral
480 Pheochromocytomas. *Journal of the Endocrine Society* 2017 **1** 1401–1407.
481 (doi:10.1210/js.2017-00135)
- 482 20. López-Jiménez E, Campos JM De, Kusak EM, Landa I, Leskelä S, Montero-Conde C,
483 Leandro-García LJ, Vallejo LA, Madrigal B, Rodríguez-Antona C, Robledo M, & Cascón A.
484 SDHC mutation in an elderly patient without familial antecedents. *Clinical Endocrinology*
485 2008 **69** 906–910. (doi:10.1111/j.1365-2265.2008.03368.x)
- 486 21. Papathomas TG, Gaal J, Corssmit EPM, Oudijk L, Korpershoek E, Heimdal K, Bayley JP,
487 Morreau H, Dooren M Van, Papaspyrou K, Schreiner T, Hansen T, Andresen PA, Restuccia
488 DF, Kessel I Van, Leenders GJLH Van, Kros JM, Looijenga LHJ, Hofland LJ, Mann W,
489 Nederveen FH Van, Mete O, Asa SL, Krijger RR De, & Dinjens WNM. Non-
490 pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate
491 dehydrogenase-related PCC-PGL syndromes: A clinicopathological and molecular analysis.
492 *European Journal of Endocrinology* 2014 **170** 1–12. (doi:10.1530/EJE-13-0623)
- 493 22. Varsavsky M, Sebastián-Ochoa A, & Torres Vela E. Coexistence of a pituitary macroadenoma
494 and multicentric paraganglioma: A strange coincidence. *Endocrinología y Nutrición* 2013. pp
495 154–156. . (doi:10.1016/j.endonu.2012.02.009)
- 496 23. Niemeijer ND, Papathomas TG, Korpershoek E, Krijger RR De, Oudijk L, Morreau H, Bayley
497 JP, Hes FJ, Jansen JC, Dinjens WNM, & Corssmit EPM. Succinate dehydrogenase (SDH)-
498 deficient pancreatic neuroendocrine tumor expands the SDH-related tumor spectrum. *Journal*
499 *of Clinical Endocrinology and Metabolism* 2015 **100** E1386–E1393. (doi:10.1210/jc.2015-
500 2689)
- 501 24. Gorospe L, Cabañero-Sánchez A, Muñoz-Molina GM, Pacios-Blanco RE, Ureña Vacas A, &
502 García-Santana E. An unusual case of mediastinal paraganglioma and pituitary adenoma.
503 *Surgery (United States)* 2017 **162** 1338–1339. (doi:10.1016/j.surg.2017.03.003)
- 504 25. Lemelin A, Lapoirie M, Abeillon J, Lasolle H, Giraud S, Philouze P, Ceruse P, Raverot G,
505 Vighetto A, & Borson-Chazot F. Pheochromocytoma, paragangliomas, and pituitary adenoma.
506 *Medicine* 2019 **98** e16594. (doi:10.1097/md.00000000000016594)
- 507 26. Guerrero Pérez F, Lisbona Gil A, Robledo M, Iglesias P, & Villabona Artero C. Adenoma
508 hipofisario asociado a feocromocitoma/paraganglioma: una nueva forma de neoplasia
509 endocrina múltiple. *Endocrinología y Nutrición* 2016 **63** 506–508.
510 (doi:10.1016/j.endonu.2016.07.007)

- 511 27. Guerrero-Pérez F, Fajardo C, Torres Vela E, Giménez-Palop O, Lisbona Gil A, Martín T,
512 González N, Díez JJ, Iglesias P, Robledo M, & Villabona C. 3P association (3PAs): Pituitary
513 adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome
514 associated with different gene mutations. *European journal of internal medicine* 2019 **69** 14–
515 19. (doi:10.1016/j.ejim.2019.08.005)
- 516 28. Dwight T, Mann K, Benn DE, Robinson BG, McKelvie P, Gill AJ, Winship I, & Clifton-Bligh
517 RJ. Familial SDHA mutation associated with pituitary adenoma and
518 pheochromocytoma/paraganglioma. *Journal of Clinical Endocrinology and Metabolism* 2013
519 **98** E1103–E1108. (doi:10.1210/jc.2013-1400)
- 520 29. Maher M, Roncaroli F, Mendoza N, Meeran K, Canham N, Kosicka-Slawinska M, Bernhard B,
521 Collier D, Drummond J, Skordilis K, Tufton N, Gontsarova A, Martin N, Korbonits M, &
522 Wernig F. A patient with a germline SDHB mutation presenting with an isolated pituitary
523 macroprolactinoma. *Endocrinology, Diabetes & Metabolism Case Reports* 2018 .
524 (doi:10.1530/edm-18-0078)
- 525 30. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M,
526 Dahia PLM, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasiaka JL,
527 Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, & Robinson BG. Clinical
528 presentation and penetrance of pheochromocytoma/paraganglioma syndromes. *Journal of*
529 *Clinical Endocrinology and Metabolism* 2006 **91** 827–836. (doi:10.1210/jc.2005-1862)
- 530 31. Caimari F & Korbonits M. Novel genetic causes of pituitary adenomas. *Clinical Cancer*
531 *Research* 2016 **22** 5030–5042. (doi:10.1158/1078-0432.CCR-16-0452)
- 532 32. Cazabat L, Libè R, Perlemoine K, René-Corail F, Burnichon N, Gimenez-Roqueplo AP,
533 Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, & Raffin-Sanson
534 ML. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene
535 in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients
536 with macroadenomas. *European journal of endocrinology* 2007 **157** 1–8. (doi:10.1530/EJE-07-
537 0181)
- 538 33. Occhi G, Trivellin G, Ceccato F, Lazzari P De, Giorgi G, Demattè S, Grimaldi F, Castello R,
539 Davi M V, Arnaldi G, Salviati L, Opocher G, Mantero F, & Scaroni C. Prevalence of AIP
540 mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B
541 status in acromegalic patients with multiple endocrine neoplasia. *European Journal of*
542 *Endocrinology* 2010 **163** 369–376. (doi:10.1530/EJE-10-0327)
- 543 34. Ferraù F, Romeo PD, Puglisi S, Ragonese M, Torre ML, Scaroni C, Occhi G, Menis E De,
544 Arnaldi G, Trimarchi F, & Cannavò S. Analysis of GPR101 and AIP genes mutations in
545 acromegaly: a multicentric study. *Endocrine* 2016 **54** 762–767. (doi:10.1007/s12020-016-
546 0862-4)
- 547 35. Hernández-Ramírez LC, Gabrovská P, Dénes J, Stals K, Trivellin G, Tilley D, Ferraù F,

- 548 Evanson J, Ellard S, Grossman AB, Roncaroli F, Gadelha MR, Korbonits M, Agha A, Akker
549 SA, Aflorei ED, Alföldi S, Arlt W, Atkinson B, Aulinas-Masó A, Aylwin SJ, Backeljauw PF,
550 Badiu C, Baldeweg S, Bano G, Barkan A, Barwell J, Bernal-González C, Besser GM, ...
551 Zammitt NN. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas:
552 Prospective Diagnosis in *AIP* Mutation Carriers. *The Journal of Clinical Endocrinology &*
553 *Metabolism* 2015 **100** E1242–E1254. (doi:10.1210/jc.2015-1869)
- 554 36. Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML,
555 Delemer B, Rohmer V, Desailoud R, Kerlan V, Chabre O, Sadoul JL, Cogne M, Caron P,
556 Cortet-Rudelli C, Lienhardt A, Raingeard I, Guedj AM, Brue T, Beckers A, Weryha G,
557 Enjalbert A, & Barlier A. Genetic analysis in young patients with sporadic pituitary
558 macroadenomas: Besides *AIP* don't forget *MEN1* genetic analysis. *European Journal of*
559 *Endocrinology* 2013 **168** 533–541. (doi:10.1530/EJE-12-0763)
- 560 37. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD,
561 Petrossians P, Elenkova A, Tabarin A, Desailoud R, Maiter D, Schürmeyer T, Cozzi R,
562 Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Fajardo Montañana C, Hana
563 V, Halaby G, Delemer B, Labarta Aizpún JI, Sonnet E, Ferrandez Longás Á, Hagelstein MT,
564 Caron P, Stalla GK, ... Beckers A. High prevalence of *AIP* gene mutations following focused
565 screening in young patients with sporadic pituitary macroadenomas. *European Journal of*
566 *Endocrinology* 2011 **165** 509–515. (doi:10.1530/EJE-11-0304)
- 567 38. Hoekstra AS & Bayley JP. The role of complex II in disease. *Biochimica et Biophysica Acta -*
568 *Bioenergetics* 2013 **1827** 543–551. (doi:10.1016/j.bbabi.2012.11.005)
- 569 39. Lecoq AL, Zizzari P, Hage M, Decourtye L, Adam C, Viengchareun S, Veldhuis JD, Geoffroy
570 V, Lombès M, Tolle V, Guillou A, Karhu A, Kappeler L, Chanson P, & Kamenický P. Mild
571 pituitary phenotype in 3- and 12-month-old *Aip*-deficient male mice. *Journal of Endocrinology*
572 2016 **231** 59–69. (doi:10.1530/JOE-16-0190)
- 573 40. Villa C, Lagonigro MS, Magri F, Koziak M, Jaffrain-Rea ML, Brauner R, Bouligand J, Junier
574 MP, Rocco F Di, Sainte-Rose C, Beckers A, Roux FX, Daly AF, & Chiovato L. Hyperplasia-
575 adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting
576 protein gene mutation. *Endocrine-Related Cancer* 2011 **18** 347–356. (doi:10.1530/ERC-11-
577 0059)
- 578 41. Stergiopoulos SG, Abu-Asab MS, Tsokos M, & Stratakis CA. Pituitary Pathology in Carney
579 Complex Patients. *Pituitary* 2004 **7** 73–82. (doi:10.1007/s11102-005-5348-y)
- 580 42. Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Scherthaner-Reiter MH,
581 Szarek E, Leal LF, Caberg JH, Castermans E, Villa C, Dimopoulos A, Chittiboina P, Xekouki
582 P, Shah N, Metzger D, Lysy PA, Ferrante E, Strebkova N, Mazerkina N, Zatelli MC, Lodish
583 M, Horvath A, Alexandre RB de, Manning AD, Levy I, Keil MF, Sierra M de la L, ... Stratakis
584 CA. Gigantism and Acromegaly Due to *Xq26* Microduplications and *GPR101* Mutation. *New*

- 585 *England Journal of Medicine* 2014 **371** 2363–2374. (doi:10.1056/NEJMoa1408028)
- 586 43. Xekouki P, Brennand A, Whitelaw B, Pacak K, & Stratakis CA. The 3PAs: An Update on the
587 Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. *Hormone and*
588 *Metabolic Research* 2019 **51** 419–436. (doi:10.1055/a-0661-0341)
- 589 44. Bardella C, Pollard PJ, & Tomlinson I. SDH mutations in cancer. *Biochimica et Biophysica*
590 *Acta - Bioenergetics* 2011 **1807** 1432–1443. (doi:10.1016/j.bbabi.2011.07.003)
- 591 45. Xekouki P & Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors:
592 could this be a new role for mitochondrial complex II and/or Krebs cycle defects? *Endocrine-*
593 *Related Cancer* 2012 **19** C33–C40. (doi:10.1530/ERC-12-0118)
- 594 46. Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. *Histopathology* 2018 **72** 106–
595 116. (doi:10.1111/his.13277)
- 596 47. Tuin K Van Der, Mensenkamp AR, Tops CMJ, Corssmit EPM, Dinjens WN, Horst-Schrivers
597 AN Van De, Jansen JC, Jong MM De, Kunst HPM, Kusters B, Leter EM, Morreau H,
598 Nesselrooij BMP Van, Oldenburg RA, Spruijt L, Hes FJ, & Timmers HJLM. Clinical aspects
599 of SDHA-related pheochromocytoma and paraganglioma: A nationwide study. *Journal of*
600 *Clinical Endocrinology and Metabolism* 2018 **103** 438–445. (doi:10.1210/jc.2017-01762)
- 601 48. Benn DiE, Zhu Y, Andrews KA, Wilding M, Duncan EL, Dwight T, Tothill RW, Burgess J,
602 Crook A, Gill AJ, Hicks RJ, Kim E, Luxford C, Marfan H, Richardson AL, Robinson B,
603 Schlosberg A, Susman R, Tacon L, Trainer A, Tucker K, Maher ER, Field M, & Clifton-Bligh
604 RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. *Journal of*
605 *Medical Genetics* 2018 **55** 729–734. (doi:10.1136/jmedgenet-2018-105427)
- 606 49. Maniam P, Zhou K, Lonergan M, Berg JN, Goudie DR, & Newey PJ. Pathogenicity and
607 Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL).
608 2018 **2** 806–816. (doi:10.1210/js.2018-00120)
- 609 50. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein
610 TE, Korf BR, McKelvey KD, Ormond KE, Richards CS, Vlangos CN, Watson M, Martin CL,
611 & Miller DT. Recommendations for reporting of secondary findings in clinical exome and
612 genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American
613 College of Medical Genetics and Genomics. *Genetics in Medicine* 2017 **19** 249–255.
614 (doi:10.1038/gim.2016.190)
- 615 51. Ishikawa T, Miyaishi S, Tachibana T, Ishizu H, Zhu BL, & Maeda H. Fatal hypothermia
616 related vacuolation of hormone-producing cells in the anterior pituitary. *Legal Medicine* 2004 **6**
617 157–163. (doi:10.1016/j.legalmed.2004.05.004)
- 618 52. Doberentz E & Madea B. Microscopic examination of pituitary glands in cases of fatal
619 accidental hypothermia. *Forensic Sciences Research* 2017 **2** 132–138.
620 (doi:10.1080/20961790.2017.1330804)
- 621

622 **Figure 1.** Repartition of VUS, LPV, and PV by gene in this study

623 **VUS:** variant of unknown significance, **LPV:** likely pathogenic variant, **PV:** pathogenic variant.

624

625

626 **Figure 2.** Comparison of the age of occurrence of PAs in genetic syndromes and controls

627 Controls: Patients with non-genetically determined PA selected as reference from the patients
628 described by Daly et al. from a Belgian population (10). *AIP* cases: 57 published cases (list available
629 upon request). *MEN1*: MEN1 cases harbouring pathogenic or likely pathogenic variants extracted
630 from the UMD-MEN1 Database (11). *PRKARIA*: Carney complex published cases listed by Cuny et
631 al.(12). *CDKN1B*: 11 MEN4 cases listed in the reviews by Alrezk et al. and Fredericksen et al. (13-
632 14).

633 * $p < 0.05$, ** $p < 0.01$ **** $p < 0.0001$.

634

635 **Table 1.** Clinical characteristics of the patients included in this study

636 F: female, M: male, Yrs: years, NA: not available, PRL: prolactin, GH: growth hormone, ACTH:
637 adrenocorticotrophic hormone, NFPA: non-functional pituitary adenoma, LH: luteinising hormone,
638 FSH: follicular-stimulating hormone, TSH: thyroid-stimulating hormone, VUS: variant of uncertain
639 significance, LPV: likely pathogenic variant, PV: pathologic variant, Macroadenoma is defined by a
640 diameter >10 mm, microadenoma is defined by a diameter <10 mm.

641

642 **Table 2:** Characteristics of patients harboring isolated pituitary adenoma and a *SDHx/MAX* likely
643 pathogenic or pathogenic variant in this study, genetics exploration and functional analysis.

644

645 **Table 3.** Patients with “3PA” syndrome with personal PPGL bearing *SDHx/MAX* mutations in the
646 literature

647 F: female, M: male, PRL: prolactin, GH: growth hormone, PPGL: pheochromocytoma/paraganglioma,
648 P: pheochromocytoma, PGL: paraganglioma, HNPGL: head and neck paraganglioma, LOH: loss of
649 heterozygosity, IHC: immunohistochemical analysis, MEN1: multiple endocrine neoplasia type 1,
650 pNET: pancreatic neuroendocrine tumor, MTC: medullar thyroid carcinoma, NFPA: non-functional
651 pituitary adenoma, PTC: papillary thyroid carcinoma, GIST: gastro-intestinal stromal tumor, HPTH:
652 hyperparathyroidism, NA: not available, NP: not performed, LPV: likely pathogenic variant, PV:
653 pathologic variant, VUS: variant of uncertain significance. *Classification using ACMG guidelines for
654 classification of sequence variants (11).

655

656 **Table 4.** Patients with “3PA” syndrome with isolated PA and familial PPGL bearing *SDHx* mutations
657 in the literature.

658 F: female, M: male, yrs: years, PA: pituitary adenoma, PRL: prolactin, P: pheochromocytoma, PGL:
659 paraganglioma, NFPA: non-functional pituitary adenoma, LOH: loss of heterozygosity, IHC:
660 immunohistochemical analysis, PV: pathologic variant, NA: not available, *Classification using
661 ACMG guidelines for classification of sequence variants (13).

662

663 **Table 5.** Characteristics of patients with pituitary adenoma in genetic and sporadic conditions

664 NA: not available; M: male; F: female, PA: pituitary adenoma, PRL: prolactinoma, macroPRL:
665 macroprolactinoma, GH: somatotropinoma, NFPA: non-functional pituitary adenoma, ACTH:
666 adrenocorticotrophic hormone, LH: luteinising hormone, FSH: follicular-stimulating hormone, TSH:
667 thyroid-stimulating hormone. *percentages are calculated from available data, patients whose data are
668 unavailable are excluded.

669 *AIP*, *MEN1*, *PRKARIA*, *CDKN1B* cases and control cases are from published cases with an individual
670 description of the cases. Non-genetically determined PA selected as reference are from the patients
671 described by Daly et al. from a Belgian population (1). The *AIP* cases were 57 published cases (a list
672 of references is available upon request). The *MEN1* cases were extracted from the UMD-MEN1
673 Database (13), the Carney complex cases were from a literature review published by Cuny et al. (14),
674 and the MEN4 (*CDKN1B*) cases were from reviews conducted by Alrezk et al. and Fredericksen et al.
675 (15, 16).

676

677 **Supplemental Table 1.** Clinical characteristics of the patients included in this study

678 F: female, M: male, NA: not available, PA: pituitary adenoma, PRL: prolactinoma, ACTH:
679 corticotropinoma, GH: somatotropinoma, NFPA: non-functional pituitary adenoma

680

681

682 **Supplemental Table 2.** Clinical and genetic characteristics of the patients harbouring pathogenic or
683 likely pathogenic variant in this study.

684 F: female, M: male, Yrs: years, PRL: prolactin, GH: growth hormone, ACTH: adrenocorticotrophic
685 hormone, NFPA: non-functional pituitary adenoma, PA: pituitary adenoma, PV: pathologic variant,
686 LPV: likely pathogenic variant; macroadenoma is defined by a diameter >10 mm, microadenoma is
687 defined by a diameter <10 mm. *Classification using ACMG guidelines for classification of sequence
688 variants (11).

689

690 **Supplemental Table 3.** Clinical and genetic characteristics of the patients with variants of uncertain
691 significance* in this study

692 F: female, M: male, NFPA: non-functional pituitary adenoma, yrs: years

693 *Classification using ACMG guidelines for classification of sequence variants (11).

For Review Only




Figure 1. Repartition of VUS, LPV, and PV by gene in this study
 VUS: variant of unknown significance, LPV: likely pathogenic variant, PV: pathogenic variant.

119x72mm (300 x 300 DPI)




Figure 2. Comparison of the age of occurrence of PAs in genetic syndromes and controls
 Controls: Patients with non-genetically determined PA selected as reference from the patients described by Daly et al. from a Belgian population (10). AIP cases: 57 published cases (list available upon request).
 MEN1: MEN1 cases harbouring pathogenic or likely pathogenic variants extracted from the UMD-MEN1 Database (11). PRKAR1A: Carney complex published cases listed by Cuny et al.(12). CDKN1B: 11 MEN4 cases listed in the reviews by Alrezk et al. and Fredericksen et al. (13-14).
 * $p < 0.05$, ** $p < 0.01$ **** $p < 0.0001$.

99x79mm (300 x 300 DPI)

1

Table 1. Clinical characteristics of the patients included in this study

	Sporadic cases		Familial cases	Total
	<30 yrs	>30 yrs		
Number of patients (n=)	133	94	36	263
Age at diagnosis (yrs) mean (range)	22.2 (9-30)	39.4 (31-78)	32.3 (8-77)	29.3 (8-78)
Sex ratio (male/female)	58 M/75 F (0.77)	62 M/32 F (1.9)	17 M/19 F (0,9)	135 M/128 F (1.05)
Size of pituitary adenoma				
Macro adenoma	95	70	22	187 (71.1%)
Micro adenoma	15	4	6	25 (9.5%)
NA	23	20	8	51 (19.4%)
Secretion of pituitary adenoma (n (%))				
PRL	52	20	14	86 (32.7%)
GH	31	36	5	72 (27.4%)
NFPA	8	6	8	22 (8.4%)
ACTH	21	3	2	26 (9.9%)
Mixed	4	8	1	13 (4.2%)
LH/FSH	1	4	0	5 (1.9%)
TSH	1	1	0	2 (0.8%)
NA	15	16	6	37 (14,1%)
Number of variants, all genes (n=)	148	115	32	295
VUS	4	3	0	7
LPV	0	2	3	5
PV	5	0	2	7

F: female, M: male, Yrs: years, NA: not available, PRL: prolactin, GH: growth hormone, ACTH: adrenocorticotrophic hormone, NFPA: non-functional pituitary adenoma, LH: luteinising hormone, FSH: follicular-stimulating hormone, TSH: thyroid-stimulating hormone, VUS: variant of uncertain significance, LPV: likely pathogenic variant, PV: pathologic variant, Macroadenoma is defined by a diameter >10 mm, microadenoma is defined by a diameter <10 mm.

2

Table 2: Characteristics of patients harboring isolated pituitary adenoma and a *SDHx/MAX* likely pathogenic or pathogenic variant in this study, genetics exploration and functional analysis.

	Case 1	Case 2	Case 3
Sex	M	M	M
Age at PA diagnosis	17	42	37
Size of PA	macro	macro	micro
Secretion of PA	PRL	PRL	PRL
Familial PA	no	no	Father and brother: macroPRL nephew: microPRL
Familial PPGL	no	no	no
PRL at diagnosis (µg/L)	91	84	55
Medical treatment	cabergoline (post operative)	carbergoline	cabergoline, bromocriptine
Surgery	yes	no	yes
Results of AIP, MEN1, CDKN1B genetic testing	normal	normal	normal
Gene	<i>SDHC</i>	<i>SDHA</i> c.757_758del, p.(Val253Cys)*	<i>SDHA</i> c.1753C>T, p.(Arg585Trp)
Variant	c.405+1G>T, p.(?)	67)	
Classification\$	PV	LPV	LPV
Histopathological examination	yes	no	yes
hormonal status	PRL+		PRL+
ki67	5%		<1%
% of P53-positive cells	10%		<1%
IHC SDH	positive	-	positive
LOH	negative	-	negative

M: Male; PRL: prolactin; PV: pathogenic variant, LPV: likely pathogenic variant; macro: macroadenoma, defined by a diameter >10 mm, micro: micro adenoma, defined by a diameter <10 mm; IHC SDH: immunohistochemistry SDH, LOH: Loss of heterozygosity
*Classification using ACMG guidelines for classification of sequence variants (11)

Table 3. Patients with “3PA” syndrome with personal PPGL bearing SDHx/MAX mutations in the literature

Patient no.	Sex	Age at PA diagnosis (yrs)	Size of PA	Secretion of PA	PPGL	Age at PPGL diagnosis	Mutation identified	Class of mutation*	LOH/IHC in PA	Familial endocrine features	References
1	M	49	Micro	PRL	P	32	<i>MAX</i> del exon 3	PV	NP	No	Daly et al. 2018
2	F	26	Macro	GH	Bilateral P	35	<i>MAX</i> del exons 1-3	PV	NP	No	Daly et al. 2018
3	M	16	Macro	GH	Metastatic bilateral P	22	<i>MAX</i> del exon 4	PV	NP	No	Daly et al. 2018
4	F	49	Macro	PRL	bilateral P	49	<i>MAX</i> c.296-1G>T, p.(?)	PV	NP	No	Roszko et al. 2017
5	F	35	Macro	NA	HNPGL, mediastinal PGL	38	<i>SDHB</i> (no info about the variant)	PV	NP	Brother: PGL and positive for mutation, mother and sister: mutation carriers	Gorospe et al. 2017
6	F	38	Macro	PRL	HNPGL, abdominal PGL	38	<i>SDHB</i> del exon 1	PV	NP	Brother: PGL, mother and sister: mutation carriers	Guerrero Perez et al. 2016
7	M	29	Macro	NFPA	P, HNPGL, abdominal	10	<i>SDHD</i> c.315-?_480+?del	PV	NP	Father and 2 brothers: mutation	Lemelin et al. 2019

					PGL					carriers	
8	F	27	NA	PRL	P	NA	<i>SDHA</i> c.91C>T, p.(Arg31*) <i>VHL</i> c.589G>A p.(Asp197Asn)	PV VUS	NP	No	Dénes J et al. 2015
9	F	49	Macro	PRL	Bilateral HNPGL	49	<i>SDHA</i> c.91C>T, p.(Arg31*)	PV	p.D38V; somatic mutation as a second hit of biallelic inactivation/ <i>SDHA</i> and <i>SDHB</i> IHC negative	NA	Niemeijer et al. 2015
10	F	53	Macro	NFPA	HNPGL	28	<i>SDHB</i> c.587G>A, p.(Cys196Tyr)	PV	LOH at <i>SDHB</i> locus/ <i>SDHB</i> staining: diffuse/intracytoplas mic vacuoles	No	Dénes J et al. 2015
11	M	33	Macro	PRL	HNPGL	33	<i>SDHB</i> c.298T>C, p.(Ser100Pro)	PV	LOH at <i>SDHB</i> locus/intracytoplasm ic vacuoles	Son of patient no. 3 in Table 4	Dénes J et al. 2015
12	F	60	Macro	PRL	HNPGL	60	<i>SDHB</i>	PV	NP	NA	Dénes J et al.

							c.423+1G>A, p.(?)				2015
13	F	50	Micro	NFPA	P	50	<i>SDHB</i> c.770dupT, p.(Asn258Glu fs*17)	LPV	NP	NA	Dénes J et al. 2015
14	M	72	NA	GH	HNPGL bilateral	70	<i>SDHB</i> c.689G>A, p.(Arg230His)	PV	NP	Sister: bilateral HNPGL, brother and niece: PA	Xekouki et al. 2015
15	F	50	Micro	PRL	metastatic PGL	47	<i>SDHB</i> c.642+1G>A, p.(?)	PV	NP	Brother: HNPGL, grandmother: GIST	Xekouki et al. 2015
16	M	53	Macro	PRL	HNPGL	38	<i>SDHC</i> c.380A>G, p.(His127Arg)	LPV	NP	Brother: PGL, cousin: PA	Dénes J et al. 2015
17	M	60	Macro	PRL	HNGPL	60	<i>SDHC</i> c256- 257insTTT, p.(Phe85dup)	LPV	NP	No	Lopez Jimenez et al. 2008
18	F	23	Macro	PRL	Bilateral HNPGL	32	<i>SDHD</i> c.242C>T, p.(Pro81Leu)	PV	NP	Sister: bilateral HNPGL, sister, aunt and grandmother:	Xekouki et al. 2015

										PA	
19	M	60	Macro	PRL	HNPGL, P	62	<i>SDHD</i> c.274G>T, p.(Asp92Tyr)	PV	LOH at <i>SDHD</i> locus/ <i>SDHB</i> IHC negative/ <i>SDHA</i> IHC positive	NA	Papathomas TG et al. 2014
20	F	56	Macro	GH	HNPGL	56	<i>SDHD</i> c.274G>T, p.(Asp92Tyr)	PV	No LOH at <i>SDHD</i> locus/ <i>SDHA</i> and <i>SDHb</i> IHC positive	Father and 2 sisters: HNPGL, sister: GIST	Papathomas TG et al. 2014
21	F	33	Macro	PRL	Bilateral HNPGL	39	<i>SDHD</i> c.242C>T, p.(Pro81Leu)	PV	NP	Brother, uncle, and aunt: HNPGL	Varsavsky et al. 2012
22	M	37	Macro	GH	HNPGL, abdominal PGL, bilateral P	37	<i>SDHD</i> c.298_301del, p.(Thr100Phe fs*34)	PV	LOH at <i>SDHD</i> locus/ <i>SDHB</i> IHC diffuse but patchy	Sister and paternal uncle: HNPGL	Xekouki et al. 2012
23	M	45	NA	NFPA	PGL	40	<i>SDHB</i> c.166_170del p.(Pro56Tyrfs *5)	PV	NP	Brother : metastatic pheo	Guerrero-Perez et al. 2019

F: female, M: male, PRL: prolactin, GH: growth hormone, PPGL: pheochromocytoma/paraganglioma, P: pheochromocytoma, PGL: paraganglioma, HNPGL: head and neck paraganglioma, LOH: loss of heterozygosity, IHC: immunohistochemical analysis, MEN1: multiple endocrine neoplasia type 1, pNET: pancreatic

neuroendocrine tumour, MTC: medullar thyroid carcinoma, NFPA: non-functional pituitary adenoma, PTC: papillary thyroid carcinoma, GIST: gastro-intestinal stromal tumour, HPTH: hyperparathyroidism, NA: not available, NP: not performed, LPV: likely pathogenic variant, PV: pathologic variant, VUS: variant of uncertain significance. *Classification using ACMG guidelines for classification of sequence variants (13).

1

For Review Only

Table 4. Patients with “3PA” syndrome with isolated PA and familial PPGL bearing SDHx mutations in the literature

Patient no.	Sex	Age at PA diagnosis (yrs)	Size of PA	Secretion of PA	Mutation	Class of mutation*	LOH/IHC in PA and cytoplasmic vacuoles	Familial features	References
1	M	30	Macro	NFPA	<i>SDHA</i> c.1873C>T, p.(His625Tyr)	PV	Negative	Mother: P and mutation carrier	Dwight T et al. 2013
2	F	56	Macro	PRL	<i>SDHB</i> c.298T>C, p.(Ser100Pro)	PV	Negative	Father: bilateral P and mutation carrier	Maher A et al. 2018
3	NA	15	NA	NA	<i>SDHB</i> c.761dup, p.(Lys255*)	PV	NA	Familial P	Benn et al. 2006
4	F	35	Macro	PRL	<i>SDHB</i> c.298T>C, p.(Ser100Pro)	PV	Positive	Mother of patient n°10 of table 3	Denes et al. 2015
5	F	31	Macro	PRL	<i>SDHB</i> deletion of exon 6 to 8	PV	LOH at <i>SDHB</i> locus/ <i>SDHB</i> IHC negative	Grandmother's first cousin: PGL	Denes et al. 2015

F: female, M: male, yrs: years, PA: pituitary adenoma, PRL: prolactin, P: pheochromocytoma, PGL: paraganglioma, NFPA: non-functional pituitary adenoma, LOH: loss of heterozygosity, IHC: immunohistochemical analysis, PV: pathologic variant, NA: not available, *Classification using ACMG guidelines for classification of sequence variants (13).

Table 5. Characteristics of patients with pituitary adenoma in genetic and sporadic conditions

	<i>SDHx</i> -mutated	<i>SDHx</i> -/ <i>MAX</i> -mutated	<i>MEN1</i> -mutated	<i>AIP</i> -mutated	<i>PRKARIA</i> -mutated	<i>CDKN1B</i> -mutated	Patients with not genetically determined PA
Number of patients (n=)	26	31	405	64	19	17	68
Sex (M/F)	11 M/14 F (1 NA)	14 M/16 F (1 NA)	155 M/250 F	39 M/25 F	8 M/11 F	2 M/12 F (3 NA)	22 M/46 F
Age at diagnosis (yrs) mean (range)	43.6 (17-72)	42.4 (16-72)	34.2 (7-82)	25.9 (10-60)	31 (16-55)	53.5 (6-79)	34.5 (1-68)
Size of PA (n, %)*							
Macro	20 (87%)	23 (85%)	190 (85%)	59 (92%)	5 (31%)	1 (17%)	29 (42%)
Micro	3 (13%)	4 (15%)	34 (15%)	5 (8%)	11 (69%)	5 (83%)	39 (58%)
NA	3	4	181	0	3	10	0
Type of secretion (n, %)*							
PRL	17 (71%)	19 (66%)	175 (78%)	7 (11%)	1 (6%)	1 (6%)	45 (66%)
macroPRL	14 (58%)	15 (52%)	136 (61%)	6 (9%)	0	NA	11 (16%)
GH	3 (12.5%)	5 (17%)	12 (5%)	51 (80%)	16 (94%)	8 (50%)	9 (13%)
NFPA	4 (16.5%)	5 (17%)	11 (5%)	3 (5%)	0	5 (31%)	10 (15%)
Mixed GH-PRL	0	0	6 (3%)	3 (5%)	0	0	0

Other (ACTH, LH/FSH, TSH)	0	0	20 (10%)	0	0	2 (ACTH- secreting, 13%)	4 (ACTH- secreting, 6%)
NA	2	2	181	0	2	1	0

NA: not available; M: male; F: female, PA: pituitary adenoma, PRL: prolactinome, macroPRL: macroprolactinoma, GH: somatotropinoma, NFPA: non-functional pituitary adenoma, ACTH: adrenocorticotropic hormone, LH: luteinising hormone, FSH: follicular-stimulating hormone, TSH: thyroid-stimulating hormone. *percentages are calculated from available data, patients whose data are unavailable are excluded.

AIP, MEN1, PRKARIA, CDKN1B cases and control cases are from published cases with an individual description of the cases. Non-genetically determined PA selected as reference are from the patients described by Daly et al. from a Belgian population (1). The *AIP* cases were 57 published cases (a list of references is available upon request). The *MEN1* cases were extracted from the UMD-MEN1 Database (15), the Carney complex cases were from a literature review published by Cuny et al. (16), and the *MEN4* cases were from reviews conducted by Alrezk et al. and Fredericksen et al. (17, 18).

Supplemental Table 1. Clinical characteristics of the patients included in this study

Patient no.	Sex	Age at diagnosis (yrs)	Size of PA	Type of PA	Other	Familial feature
1	F	17	NA	PRL		Sister: PA
2	F	39	NA	NA		Familial history of PA
3	M	22	Macro	ACTH	Aggressive, recurrence	Sporadic
4	F	13	Macro	PRL		Niece: PA
5	M	33	Macro	PRL		Sporadic
6	M	23	Macro	PRL	Recurrence	Sporadic
7	F	25	NA	ACTH		Sporadic
8	M	40	Macro	NFPA		Sporadic
9	M	8	NA	ACTH		Mother: prolactinoma Great uncle: PA
10	F	30	NA	GH		Sporadic
11	F	19	Macro	NFPA		Sporadic
12	M	16	Micro	PRL		Sporadic
13	F	18	Micro	ACTH		Sporadic
14	M	45	NA	PRL		Sporadic
15	M	31	Macro	PRL		Sporadic
16	F	49	NA			Sporadic
17	M	30	Macro	PRL		Sporadic
18	M	40	NA	GH	Aggressive and resistant to treatment	Sporadic
19	M	34	NA	GH		Sporadic
20	M	19	Macro	PRL		Sporadic
21	F	25	NA	ACTH		Sporadic
22	F	24	Macro	PRL		Sporadic
23	F	17	Micro	PRL		Sporadic
24	M	16	Macro	PRL		Sporadic
25	F	27	Macro	NA		Sporadic
26	M	39	Macro	PRL		Sporadic
27	M	24	NA	GH	Apoplexy	Sporadic
28	M	33	Macro	GH	Aggressive	Sporadic
29	F	27	NA	ACTH		Sporadic
30	F	21	Micro	ACTH		Sporadic
31	M	50	Micro	PRL		Father: macroprolactinoma
32	F	53	NA	GH		Sporadic
33	M	26	Macro	ACTH		Sporadic
34	M	47	Macro	PRL		Sporadic
35	F	19	Macro	NA		Sporadic
36	F	25	NA	GH		Sporadic
37	M	23	Macro	PRL	Recurrence	Sporadic
38	F	34	NA	GH		Sporadic
39	F	16	Micro	PRL		Brother: macroprolactinoma
40	M	27	NA	ACTH		Sporadic
41	M	18	Micro	ACTH		Sporadic
42	M	28	NA	NA		Father: acromegaly Brother: NFPA
43	M	36	Macro	ACTH		Sporadic

44	M	31	Macro	PRL		Sporadic
45	M	24	Macro	PRL		Sporadic
46	F	17	Macro	GH		Sporadic
47	M	30	Macro	NA		Sporadic
48	M	54	NA	NA		Sporadic
49	F	17	Macro	NFPA		Sporadic
50	F	33	Macro	NA		Sporadic
51	F	26	Micro	PRL		Sporadic
52	F	16	Macro	ACTH		Sporadic
53	M	41	Macro	GH	Resistant to treatment	Sporadic
54	M	18	NA	PRL		Grandfather: PA
55	F	22	Macro	ACTH		Sporadic
56	F	34	Macro	NA		Sporadic
57	F	29	Macro	NA		Sporadic
58	M	21	Macro	PRL		Aunt: PA
59	M	14	Micro	ACTH		Sporadic
60	F	20	Macro	GH		Sporadic
61	F	21	Macro	NA		Niece: acromegaly
62	M	19	Macro	PRL		Sporadic
63	F	37	Micro	GH		Sporadic
64	M	22	Macro	PRL		Sporadic
65	F	37	Macro	GH		Sporadic
66	F	28	Macro	GH		Sporadic
67	M	27	Macro	Mixed PRL- ACTH		Sporadic
68	F	38	Macro	LH-FSH		Sporadic
69	F	21	Macro	PRL		Sporadic
70	F	19	Micro	PRL	Resistant to treatment	Sporadic
71	M	29	Macro	GH		Sporadic
72	M	33	Macro	PRL		Sporadic
73	M	64	Macro	LH-FSH		Sporadic
74	F	31	Macro	GH		Sporadic
75	M	14	Micro	ACTH		Sporadic
76	M	33	Macro	NFPA	Panhypopituitarism	Sporadic
77	M	34	Macro	Mixed PRL-GH	Aggressive	Sporadic
78	M	29	Macro	PRL		Sporadic
79	M	35	Macro	NA		Sporadic
80	M	31	Macro	mixed PRL-GH		Sporadic
81	F	44	Macro	PRL		Sporadic
82	M	28	Macro	NFPA		Sporadic
83	M	25	Macro	GH	Invasive	Sporadic
84	M	39	NA	NA		Sporadic
85	F	37	Macro	NFPA		Sporadic
86	M	41	Macro	GH		Sporadic
87	F	60	Micro	NFPA		Mother: acromegaly
88	M	34	NA	GH		Sporadic

89	F	16	Macro	PRL		Aunt and 3 cousins: PA
90	F	25	Macro	PRL		Sporadic
91	F	48	NA	NA		Sporadic
92	F	21	Macro	PRL		Sporadic
93	M	40	Macro	NFPA		Brother: PA
94	M	40	Macro	NFPA		Brother: PA
95	F	20	Macro	PRL		Sporadic
96	M	28	Macro	PRL		Sporadic
97	M	17	Macro	PRL		Sporadic
98	F	35	Macro	GH		Sporadic
99	M	39	Macro	GH		Sporadic
100	F	25	Micro	GH		Sister: prolactinoma
101	F	27	Micro	NFPA		Mother: microprolactinoma
102	M	11	Macro	NFPA		Father: somatotropinoma
103	F	30	Macro	NFPA		Sporadic
104	F	33	Macro	GH		Sporadic
105	F	15	NA	PRL		Sporadic
106	F	30	Micro	ACTH		Sporadic
107	F	22	Macro	GH		Sporadic
108	M	30	Macro	NFPA	Recurrence	Sporadic
109	M	31	Macro	GH		Sporadic
110	F	35	Macro	GH		Sporadic
111	F	27	Macro	mixed GH- LH/FSH		Sporadic
112	M	35	Macro	GH		Sporadic
113	F	29	NA	NA		Sporadic
114	M	67	NA	NA	Apoplexy	Brother: acromegaly
115	F	20	Micro	PRL		Sporadic
116	F	33	Macro	NFPA	Recurrence	Sporadic
117	M	28	Macro	GH		Sporadic
118	F	16	Macro	PRL		Grandmother: PA
119	M	39	Macro	GH		Sporadic
120	F	17	Macro	GH		Sporadic
121	F	30	NA	ACTH	Recurrence	Sporadic
122	M	28	Macro	LH		Sporadic
123	F	15	Macro	PRL		Sporadic
124	F	34	Macro	GH		Sporadic
125	M	35	Macro	Mixed PRL-GH		Sporadic
126	F	27	Macro	PRL		Sporadic
127	M	16	Macro	GH		Sporadic
128	M	16	Macro	PRL		Mother and cousin: PA
129	M	15	NA	PRL		Sporadic
130	F	20	Macro	NFPA		Great aunt: PA
131	M	37	Micro	PRL		Father and brother: macroprolactinoma Nephew: macroprolactina

132	F	16	Macro	PRL		Sporadic
133	M	15	NA	ACTH		Sporadic
134	F	15	Macro	GH		Sporadic
135	M	24	Macro	NA		Sporadic
136	M	26	Macro	NA	Invasive, recurrence	Sporadic
137	F	24	Macro	Mixed PRL-GH		Sporadic
138	F	11	Macro	PRL		Sporadic
139	F	18	NA	GH		Sporadic
140	F	27	NA	GH		Sporadic
141	M	38	Macro	PRL		Sporadic
142	F	16	Macro	GH		Sporadic
143	M	20	Macro	NA		Mother: ACTH-secreting PA
144	F	30	Macro	Mixed PRL-GH		Son: Macro PA
145	F	15	NA	PRL		Sporadic
146	M	22	Macro	PRL		Sporadic
147	F	12	Macro	PRL		Sporadic
148	F	20	Macro	NA		Sporadic
149	F	20	Macro	NFPA		Sporadic
150	M	31	Macro	NA		Sporadic
151	M	25	Macro	ACTH		Sporadic
152	M	18	Macro	PRL		Sporadic
153	M	24	Macro	NA		Sporadic
154	F	33	Macro	ACTH		Sporadic
155	F	31	Macro	NFPA		Sporadic
156	F	32	Macro	NA		Sporadic
157	F	31	Macro	GH	Resistant to treatment	Sporadic
158	M	64	NA	GH		Sporadic
159	F	26	Macro	PRL		Sporadic
160	M	23	Macro	GH		Sporadic
161	F	31	Micro	Mixed PRL-GH		Sporadic
162	M	46	NA	GH		Sporadic
163	M	17	Macro	PRL		Sporadic
164	M	34	Macro	GH		Sporadic
165	F	36	Macro	NA		Sporadic
166	M	27	Macro	PRL		Sporadic
167	M	26	micro	ACTH		Sporadic
168	F	50	Macro	NA		Sister: prolactinome
169	F	46	Macro	GH		Sporadic
170	M	52	Macro	GH		Sporadic
171	M	18	Macro	PRL		Sporadic
172	M	24	Macro	NA	Alpha sub-unit PA	Sporadic
173	F	12	NA	NA		Sporadic
174	M	19	Macro	PRL		Sporadic
175	F	50	NA	NFPA		Brother: PA
176	M	35	Macro	Mixed PRL-GH		Sporadic
177	F	25	Macro	PRL		Sporadic
178	M	45	NA	GH		Sporadic
179	M	42	Macro	Mixed		Sporadic

				PRL-GH		
180	F	38	NA	NA		Sporadic
181	F	21	Macro	NFPA		Sporadic
182	H	45	Macro	PRL		Sporadic
183	M	29	Macro	PRL		Sporadic
184	M	22	Macro	GH		Sporadic
185	M	62	NA	NA		Sporadic
186	M	28	Macro	GH		Sporadic
187	M	44	Macro	GH		Sporadic
188	M	78	Macro	ACTH		Sporadic
189	F	53	NA	GH		Sister: acromegaly
190	F	24	NA	TSH		Sporadic
191	F	61	NA	GH		Sporadic
192	M	36	NA	GH		Sporadic
193	F	23	Macro	ACTH		Father: NFPA
194	F	29	NA	NA		Sporadic
195	F	12	NA	PRL		Sporadic
196	F	36	Macro	GH		Sporadic
197	F	21	Macro	GH		Sporadic
198	M	49	Macro	GH		Cousin: GH-secreting macroadenoma
199	F	14	Micro	PRL		Sporadic
200	M	42	Macro	NA		Sporadic
201	M	19	Macro	GH		Sporadic
202	F	25	Macro	GH		Sporadic
203	F	29	Macro	GH		Sporadic
204	F	37	Macro	GH		Sporadic
205	F	30	Macro	PRL		Cousin: PA
206	F	13	Macro	PRL		Mother: macroprolactinoma
207	F	28	Macro	GH	Apoplexy and panhypopituitarism	Sporadic
208	F	17	NA	PRL		Sporadic
209	F	29	NA	NA		Sporadic
210	M	23	Macro	PRL		Sporadic
211	F	16	Macro	PRL		Sporadic
212	M	15	NA	ACTH		Sporadic
213	F	47	Macro	mixed GH-ACTH		Sporadic
214	M	36	Macro	PRL		Sporadic
215	M	74	Macro	NFPA		Son: NFPA
216	M	21	Macro	PRL		Sporadic
217	M	33	Macro	PRL		Sporadic
218	M	32	Macro	NA		Sporadic
219	M	38	Macro	PRL		Sporadic
220	M	42	Macro	PRL		Sporadic
221	M	30	Macro	PRL		Sporadic
222	M	38	Micro	GH		Sporadic
223	M	31	Macro	PRL		Sporadic
224	F	21	Micro	PRL		Sporadic
225	M	31	NA	NA		Sporadic

226	F	15	Macro	GH		Sporadic
227	M	34	Macro	LH-FSH		Sporadic
228	F	30	Macro	NA		Sporadic
229	M	41	Macro	TSH		Sporadic
230	F	77	Macro	GH		Niece: mixed macroadenoma (GH-PRL)
231	M	37	Macro	GH		Sporadic
232	M	22	Macro	PRL		Cousin: PA
233	M	36	Macro	PRL		Sporadic
234	F	30	Macro	PRL	Recurrence	Sporadic
235	M	33	Macro	PRL		Sporadic
236	F	26	NA	GH		Sporadic
237	M	34	Macro	PRL		Sister: PA
238	M	23	Macro	NA		Sporadic
239	M	57	Macro	GH		Sporadic
240	M	21	Macro	PRL		Sporadic
241	M	30	Macro	GH		Sporadic
242	F	16	Macro	NFPA		Sporadic
243	M	23	Macro	GH		Sporadic
244	F	36	NA	GH		Sporadic
245	F	36	NA	NA		Sporadic
246	F	16	Macro	PRL		Sporadic
247	M	35	Macro	FSH		Sporadic
248	F	22	Macro	GH		Sporadic
249	F	48	Micro	NFPA		Sporadic
250	F	28	Macro	ACTH		Sporadic
251	M	31	Macro	GH		Sister: prolactinoma
252	M	33	Macro	PRL		Sporadic
253	F	9	Macro	PRL		Sporadic
254	M	29	Macro	Mixed GH-TSH		Sporadic
255	F	27	Macro	GH		Sporadic
256	F	21	Micro	PRL		Sporadic
257	M	37	Macro	PRL		Sporadic
258	M	55	Macro	GH		Sporadic
259	M	14	Macro	ACTH		Sporadic
260	M	44	Macro	PRL		Sporadic
261	F	29	Macro	PRL		Sporadic
262	M	25	Macro	GH		Sporadic
263	M	40	Macro	Mixed PRL- FSH		Sporadic

F: female, M: male, NA: not available, PA: pituitary adenoma, PRL: prolactinoma, ACTH: corticotropinoma, GH: somatotropinoma, NFPA: non-functional pituitary adenoma

Supplemental table 2. Clinical and genetic characteristics of the patients harbouring a pathogenic or likely pathogenic variants in this study

Patient no.	Sex	Age at diagnosis (yrs)	Phenotype of pituitary adenoma	Familial feature	Gene	HGVSc	HGVSp	Genotype	Consequence	Classification*
1	M	17	Macroprolactinoma	Sporadic	<i>SD</i> <i>HC</i>	c.405+1G >T	p.(?)	Heterozygous	Splicing variant	PV
2	M	42	Macroprolactinoma	Sporadic	<i>SD</i> <i>HA</i>	c.757_75 8del	p.(Val253Cys*67)	Heterozygous	Frameshift variant	PV
3	M	37	Microprolactinoma	Father and brother: macroprolactinoma nephew: microprolactinoma	<i>SD</i> <i>HA</i>	c.1753C> T	p.(Arg585Trp)	Heterozygous	Missense variant	LPV
4	F	19	Macroadenoma NFPA	Sporadic	<i>AIP</i>	c.350del G	p.(Gly117Ala*39)	Heterozygous	Frameshift variant	PV
5	M	21	Macroprolactinoma	Aunt: PA	<i>AIP</i>	c.805_82 5dup	p.(Phe269_His275dup)	Heterozygous	In-frame insertion	LPV
6	M	23	GH-producing macroadenoma	Sporadic	<i>AIP</i>	c.601A> T	p.(Lys201*)	Heterozygous	Nonsense variant	PV
7	M	22	Macroprolactinoma	Cousin: PA	<i>AIP</i>	c.55C>T	p.(Gln19*)	Heterozygous	Nonsense variant	PV
8	M	22	GH-producing macroadenoma	Sporadic	<i>AIP</i>	c.853C>T	p.(Gln285*)	Heterozygous	Nonsense variant	PV
9	F	30	Mixed	Son: Macro PA	<i>AIP</i>	c.911G>A	p.(Arg304G)	Heterozygous	Missense	LPV

			Macroadenoma (PRL-GH)				ln)	gous	variant	
10	F	47	Mixed macroadenoma (GH- ACTH)	Sporadic	<i>AIP</i>	c.865G>A	p.(Ala289T hr)	Heterozy gous	Missense variant	LPV
11	F	20	Macroadenoma NFPA	Maternal PA	great-aunt: <i>ME</i> <i>NI</i>	c.1314delC	p.(Val441C ys*4)	Heterozy gous	Frameshift variant	PV
12	F	11	Macroprolactinoma	Sporadic	<i>ME</i> <i>NI</i>	c.574C>T	p.(Gln192*)	Heterozy gous	Nonsenseva riant	PV

*Classification using ACMG guidelines for classification of sequence variants (11).

F: female, M: male, Yrs: years, PRL: prolactin, GH: growth hormone, ACTH: adrenocorticotrophic hormone, NFPA: non-functional pituitary adenoma, PA: pituitary adenoma, PV: pathologic variant, LPV: likely pathogenic variant, . Macroadenoma is defined by a diameter >10 mm, microadenoma is defined by a diameter <10 mm.

Supplemental Table 3. Clinical and genetic characteristics of the patients with variants of uncertain significance* in this study

Patient no.	Sex	Age at diagnosis (yrs)	Phenotype of pituitary adenoma	Familial feature	Gene	HGVSc	HGVSp	Genotype	Consequence
1	F	53	Somatotropinoma	Sporadic	<i>AIP</i>	c.326C>T	p.(Ala109Val)	Heterozygous	Missense variant
2	M	15	Prolactinoma	Sporadic	<i>CDKN1B</i>	c.586C>T	p.(Arg196Cys)	Heterozygous	Missense variant
3	M	31	Macroprolactinoma	Sporadic	<i>MEN1</i>	c.903C>T	p.(=)	Heterozygous	Synonymous variant
4	F	26	Somatotropinoma	Sporadic	<i>SDHA</i>	c.512G>A	p.(Arg171His)	Heterozygous	Missense variant
5	M	33	Macroadenoma NFPA	Sporadic	<i>SDHB</i>	c.312C>T	p.(=)	Heterozygous	Synonymous variant
6	F	25	Macroprolactinoma	Sporadic	<i>SDHD</i>	c.110A>G	p.(Asp37Gly)	Heterozygous	Missense variant
7	F	29	Macroprolactinoma	Sporadic	<i>SDHD</i>	c.158C>T	p.(Pro53Leu)	Heterozygous	Missense variant

F: female, M: male, NFPA: non-functional pituitary adenoma, yrs: years

*Classification using ACMG guidelines for classification of sequence variants (11).